Thomas Weisel Starts Lexicon (LXRX) at Overweight, $2.50 Price Target
Tweet Send to a Friend
Thomas Weisel initiates coverage on Lexicon Pharmaceuticals (Nasdaq: LXRX) with an Overweight rating and a $2.50 price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
